161 related articles for article (PubMed ID: 19958628)
1. [Efficacy of cetuximab combined with chemotherapy on advanced colorectal cancer: a report of 53 cases].
Guo GF; Xia LP; Zhang B; Jiang WQ; Liu MZ; Hu PL; Chen XX; Qiu HJ; Zhou FF
Ai Zheng; 2009 Dec; 28(12):1317-23. PubMed ID: 19958628
[TBL] [Abstract][Full Text] [Related]
2. [Efficacy of cetuximab combined with chemotherapy for patients with advanced colorectal cancer and unclear K-ras status].
Guo GF; Xia LP; Qiu HJ; Xu RH; Zhang B; Jiang WQ; Zhou FF; Wang F
Zhonghua Zhong Liu Za Zhi; 2010 Oct; 32(10):777-81. PubMed ID: 21163071
[TBL] [Abstract][Full Text] [Related]
3. [Efficacy of CPT-11 combined 5-FU/CF (FOLFIRI) regimen on advanced colorectal cancer].
Luo HY; Li YH; Zhang L; Jiang WQ; Shi YX; Wang F; He YJ; Xu RH
Ai Zheng; 2007 Aug; 26(8):905-8. PubMed ID: 17697557
[TBL] [Abstract][Full Text] [Related]
4. [Efficacy of FORFIRI regimen on oxaliplatin-based chemotherapy-failed advanced colorectal cancer].
Li YH; Wang FH; Zhang DS; Wang ZQ; Feng F; Zhang L; Xu RH; Jiang WQ; He YJ
Ai Zheng; 2009 Sep; 28(9):913-8. PubMed ID: 19728906
[TBL] [Abstract][Full Text] [Related]
5. Oxaliplatin, irinotecan and cetuximab in advanced gastric cancer. A multicenter phase II trial (Gastric-2) of the Arbeitsgemeinschaft Medikamentose Tumortherapie (AGMT).
Wöll E; Greil R; Eisterer W; Bechter O; Fridrik MA; Grünberger B; Zabernigg A; Mayrbäurl B; Russ G; Dlaska M; Obrist P; Thaler J
Anticancer Res; 2011 Dec; 31(12):4439-43. PubMed ID: 22199312
[TBL] [Abstract][Full Text] [Related]
6. Comparison of cetuximab to bevacizumab as the first-line bio-chemotherapy for patients with metastatic colorectal cancer: superior progression-free survival is restricted to patients with measurable tumors and objective tumor response--a retrospective study.
Yang YH; Lin JK; Chen WS; Lin TC; Yang SH; Jiang JK; Lan YT; Lin CC; Yen CC; Tzeng CH; Teng HW
J Cancer Res Clin Oncol; 2014 Nov; 140(11):1927-36. PubMed ID: 24934725
[TBL] [Abstract][Full Text] [Related]
7. [Cetuximab in combination with chemotherapy for patients with gastrointestinal cancer].
Zhang XT; Shen L; Zhang XD; Li J; Zhang ZT
Zhonghua Zhong Liu Za Zhi; 2008 May; 30(5):385-8. PubMed ID: 18953842
[TBL] [Abstract][Full Text] [Related]
8. Cetuximab and circadian chronomodulated chemotherapy as salvage treatment for metastatic colorectal cancer (mCRC): safety, efficacy and improved secondary surgical resectability.
Lévi F; Karaboué A; Gorden L; Innominato PF; Saffroy R; Giacchetti S; Hauteville D; Guettier C; Adam R; Bouchahda M
Cancer Chemother Pharmacol; 2011 Feb; 67(2):339-48. PubMed ID: 20401611
[TBL] [Abstract][Full Text] [Related]
9. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.
Cunningham D; Humblet Y; Siena S; Khayat D; Bleiberg H; Santoro A; Bets D; Mueser M; Harstrick A; Verslype C; Chau I; Van Cutsem E
N Engl J Med; 2004 Jul; 351(4):337-45. PubMed ID: 15269313
[TBL] [Abstract][Full Text] [Related]
10. Impact of young age on treatment efficacy and safety in advanced colorectal cancer: a pooled analysis of patients from nine first-line phase III chemotherapy trials.
Blanke CD; Bot BM; Thomas DM; Bleyer A; Kohne CH; Seymour MT; de Gramont A; Goldberg RM; Sargent DJ
J Clin Oncol; 2011 Jul; 29(20):2781-6. PubMed ID: 21646604
[TBL] [Abstract][Full Text] [Related]
11. [Short-term efficacy of cetuximab combined with radiotherapy or chemotherapy on head and neck cancer: a report of 11 cases].
Xia LP; Zhang B; Liu MZ; Hu PL; Chen XX; Guo GF; Qiu HJ; Rong YM; Qian SY; Zhou FF; Huang YY; Wang TL
Ai Zheng; 2009 Sep; 28(9):977-82. PubMed ID: 19728918
[TBL] [Abstract][Full Text] [Related]
12. [Analysis on safety and preliminary efficacy of dose-modified regimen of 5-fluorouracil plus oxaliplatin and irinotecan (FOLFOXIRI) in advanced colorectal cancer].
Cai Y; Deng R; Hu H; Zhang J; Ling J; Wu Z; Yang L; Li J; Deng Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Sep; 21(9):1045-1050. PubMed ID: 30269326
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of irinotecan and cetuximab given every 2 weeks as second-line therapy for advanced colorectal cancer.
Carneiro BA; Ramanathan RK; Fakih MG; Krishnamurthi SS; Lembersky BC; Stoller RG; Lancaster SL; Pinkerton RA; Crandall TL; Schmotzer AR; Potter DM; Bahary N
Clin Colorectal Cancer; 2012 Mar; 11(1):53-9. PubMed ID: 21813336
[TBL] [Abstract][Full Text] [Related]
14. A phase II trial of FOLFOX6 and cetuximab in the first-line treatment of patients with metastatic colorectal cancer.
Boccia RV; Cosgriff TM; Headley DL; Badarinath S; Dakhil SR
Clin Colorectal Cancer; 2010 Apr; 9(2):102-7. PubMed ID: 20378504
[TBL] [Abstract][Full Text] [Related]
15. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer.
Sobrero AF; Maurel J; Fehrenbacher L; Scheithauer W; Abubakr YA; Lutz MP; Vega-Villegas ME; Eng C; Steinhauer EU; Prausova J; Lenz HJ; Borg C; Middleton G; Kröning H; Luppi G; Kisker O; Zubel A; Langer C; Kopit J; Burris HA
J Clin Oncol; 2008 May; 26(14):2311-9. PubMed ID: 18390971
[TBL] [Abstract][Full Text] [Related]
16. Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil.
Pfeiffer P; Nielsen D; Bjerregaard J; Qvortrup C; Yilmaz M; Jensen B
Ann Oncol; 2008 Jun; 19(6):1141-5. PubMed ID: 18281264
[TBL] [Abstract][Full Text] [Related]
17. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.
Venook AP; Niedzwiecki D; Lenz HJ; Innocenti F; Fruth B; Meyerhardt JA; Schrag D; Greene C; O'Neil BH; Atkins JN; Berry S; Polite BN; O'Reilly EM; Goldberg RM; Hochster HS; Schilsky RL; Bertagnolli MM; El-Khoueiry AB; Watson P; Benson AB; Mulkerin DL; Mayer RJ; Blanke C
JAMA; 2017 Jun; 317(23):2392-2401. PubMed ID: 28632865
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of cetuximab/irinotecan in chemotherapy-refractory metastatic colorectal adenocarcinomas: a clinical practice setting, multicenter experience.
Gebbia V; Del Prete S; Borsellino N; Ferraù F; Tralongo P; Verderame F; Leonardi V; Capasso E; Maiello E; Bordonaro R; Stinco S; Agostara B; Barone C
Clin Colorectal Cancer; 2006 Mar; 5(6):422-8. PubMed ID: 16635281
[TBL] [Abstract][Full Text] [Related]
19. Anti-EGFR (cetuximab) combined with irinotecan for treatment of elderly patients with metastatic colorectal cancer (mCRC).
Abdelwahab S; Azmy A; Abdel-Aziz H; Salim H; Mahmoud A
J Cancer Res Clin Oncol; 2012 Sep; 138(9):1487-92. PubMed ID: 22526166
[TBL] [Abstract][Full Text] [Related]
20. Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: results of a Phase II MARGIT trial.
Horisberger K; Treschl A; Mai S; Barreto-Miranda M; Kienle P; Ströbel P; Erben P; Woernle C; Dinter D; Kähler G; Hochhaus A; Post S; Willeke F; Wenz F; Hofheinz RD;
Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1487-93. PubMed ID: 19131187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
